StreetInsider.com News Articles

Form 8-K LIFECORE BIOMEDICAL, For: Oct 16

Tue, 20 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261020/27210880.html

Lifecore Biomedical to Participate at Upcoming Industry Conferences

Wed, 07 Oct 2026 16:05:00 -0400

CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events.

At each conference, Lifecore leaders will host meetings with prospective customers to discuss process development and manufacturing services for injectable programs. Details regarding Lifecore’s participation are as follows:

CDMO Live Americas:
Booth number: C19
Conference Dates: October 19-21, 2026
Location: Boston, MA
Partnership Opportunities in Drug Development (PODD)
Booth number: 109
Conference Dates: October 29-30, 2026
Location: Boston, MA

Ryan Swanson, Ph.D.,

Lifecore Biomedical to Participate at Upcoming Industry Conferences

Wed, 07 Oct 2026 16:05:00 -0400

CDMO Live Americas:
Booth number: C19
Conference Dates: October 19-21, 2026
Location: Boston, MA
Partnership Opportunities in Drug Development (PODD)
Booth number: 109
Conference Dates: October 29-30, 2026
Location: Boston, MA

Ryan Swanson, Ph.D.,

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: WYNNEFIELD PARTNERS SMALL CAP VALUE LP I

Tue, 29 Sep 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260929/27122695.html

Form 8-K LIFECORE BIOMEDICAL, For: Sep 24

Tue, 29 Sep 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260929/27122618.html

Barrington Research Downgrades Lifecore Biomedical (LFCR) to Market Perform

Tue, 29 Sep 2026 07:35:35 -0400

Barrington Research analyst Michael Petusky downgraded Lifecore Biomedical (NASDAQ: LFCR) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Lifecore Biomedical click here. For more ratings news on Lifecore Biomedical click here.

Shares of Lifecore Biomedical closed at $6.52 yesterday.

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: Legion Partners Asset Management, LLC

Mon, 28 Sep 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260928/27115687.html

Craig-Hallum Downgrades Lifecore Biomedical (LFCR) to Hold

Mon, 28 Sep 2026 14:01:13 -0400

Craig-Hallum analyst Matt Hewitt downgraded Lifecore Biomedical (NASDAQ: LFCR) from Buy to Hold with a price target of $6.28.

For an analyst ratings summary and ratings history on Lifecore Biomedical click here. For more ratings news on Lifecore Biomedical click here.

Shares of Lifecore Biomedical closed at $4.20 yesterday.

William Blair Downgrades Lifecore Biomedical (LFCR) to Market Perform

Mon, 28 Sep 2026 12:24:28 -0400

William Blair analyst Max Smock downgraded Lifecore Biomedical (NASDAQ: LFCR) from Outperform to Market Perform.

The analyst comments "With the stock trading at approximately $6.60 intraday, we believe the current spread above the $6.28 pre-CVR deal price appropriately reflects the risks associated with milestone achievement and deal timing. Thus, we see limited opportunity for share from here, and as a result, we are downgrading the stock to Market Perform."

For an analyst ratings summary and ratings history on Lifecore Biomedical click here. For more ratings news on Lifecore Biomedical click here.

Shares of Lifecore Biomedical closed at $4.20 yesterday.

Form DEFA14A LIFECORE BIOMEDICAL,

Mon, 28 Sep 2026 08:57:00 -0400

si-local-file:///var/storage/secattach/20260928/27110767.html

Form 8-K LIFECORE BIOMEDICAL, For: Sep 27

Mon, 28 Sep 2026 08:54:00 -0400

si-local-file:///var/storage/secattach/20260928/27110748.html

Webster Equity Partners to acquire Lifecore Biomedical for up to $664M

Mon, 28 Sep 2026 08:45:17 -0400

Lifecore Biomedical, Inc. (Nasdaq: LFCR) has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, assuming full achievement of certain performance milestones, according to a company statement.

Under the terms of the agreement, common stockholders will receive $6.28 per share in cash at closing, representing a 49.5% premium to Lifecore's closing price on September 25, 2026, the last full trading day before the merger agreement was signed. Each common stockholder will also receive one non-tradable contingent value right (CVR) per share.

Holders of Series A Preferred Stock will receive a

Lifecore Biomedical to be Acquired by Webster Equity Partners

Mon, 28 Sep 2026 08:45:00 -0400

Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium
Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at Closing
Both Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance Milestones
Stockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CVR at Full Performance Milestone Payments
Transaction Expected to Support Lifecore’s Growth Objectives

CHASKA, Minn. and WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.

Lifecore Biomedical to be Acquired by Webster Equity Partners

Mon, 28 Sep 2026 08:45:00 -0400

Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium
Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at Closing
Both Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance Milestones
Stockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CVR at Full Performance Milestone Payments
Transaction Expected to Support Lifecore’s Growth Objectives

CHASKA, Minn. and WALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.

Lifecore Biomedical (LFCR) Tops Q2 EPS by 4c

Wed, 05 Aug 2026 07:32:43 -0400

Lifecore Biomedical (NASDAQ: LFCR) reported Q2 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $34.17 million versus the consensus estimate of $31.66 million.

For earnings history and earnings-related data on Lifecore Biomedical (LFCR) click here.

Form 10-Q LIFECORE BIOMEDICAL, For: Jun 30

Wed, 05 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260805/26870263.html

Form 10-Q LIFECORE BIOMEDICAL, For: Jun 30

Wed, 05 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260805/26870263.html

Form 10-Q LIFECORE BIOMEDICAL, For: Jun 30

Wed, 05 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260805/26870263.html

Form 8-K LIFECORE BIOMEDICAL, For: Aug 05

Wed, 05 Aug 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26870249.html

Form 8-K LIFECORE BIOMEDICAL, For: Aug 05

Wed, 05 Aug 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26870249.html

Form 8-K LIFECORE BIOMEDICAL, For: Aug 05

Wed, 05 Aug 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26870249.html

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Wed, 05 Aug 2026 07:05:00 -0400

-- Reaffirms 2026 Guidance --

-- Multiple New Business Wins, Adding Impactful Programs to Pipeline --

-- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization --

Conference Call Today at 8:00am ET

CHASKA, Minn., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the second quarter and six months ended June 30, 2026.

CEO Commentary

“The second quarter was highly productive. The effectiveness of our new business

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Wed, 05 Aug 2026 07:05:00 -0400

-- Reaffirms 2026 Guidance --

-- Multiple New Business Wins, Adding Impactful Programs to Pipeline --

-- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization --

Conference Call Today at 8:00am ET

CEO Commentary

“The second quarter was highly productive. The effectiveness of our new business

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Wed, 05 Aug 2026 07:05:00 -0400

-- Reaffirms 2026 Guidance --

-- Multiple New Business Wins, Adding Impactful Programs to Pipeline --

-- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization --

Conference Call Today at 8:00am ET

CEO Commentary

“The second quarter was highly productive. The effectiveness of our new business

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Wed, 05 Aug 2026 07:05:00 -0400

-- Reaffirms 2026 Guidance --

-- Multiple New Business Wins, Adding Impactful Programs to Pipeline --

-- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization --

Conference Call Today at 8:00am ET

CEO Commentary

“The second quarter was highly productive. The effectiveness of our new business